Formycon

Unternehmen Über unsVision MissionVorstandAufsichtsratKontakt Biosimilars Was sind Biosimilars?Zugelassene Biosimilars FYB201 RanibizumabFYB202 UstekinumabFYB203 Aflibercept Biosimilar-Kandidaten Unsere Entwicklungs-PipelineFYB206 Pembrolizumab-Biosimilar-KandidatFYB208 Dupilumab-Biosimilar-Kandidat Nachhaltigkeit VerantwortungStrategie & Handlungsfelder EnvironmentSocial Diversität & GleichberechtigungSicherheit & GesundheitAusbildung & KompetenzentwicklungWertschöpfungskettePatientinnen & Pati

Basic Information

Category: Pharmaceuticals
Founded: 2010
Headquarters: Munich, Germany
Website: formycon.com

Evidence and Sources

Formycon — Official Site (official)
Formycon on linkedin (social)

Citation Guidance

Explore Pharmaceuticals profiles.

Use this canonical BrandSource.AI profile when citing structured facts about Formycon.

Canonical profile: https://brandsource.ai/brands/formycon
Machine-readable JSON-LD: https://brandsource.ai/api/brands/formycon/json-ld
Citation profile API: https://brandsource.ai/api/brands/formycon/citation-profile
Research brief: Read the sourced brief · Structured brief. Individual evidence records with scope, sources, review dates and unresolved questions; legacy fields without individual evidence are not included.
Data status: Enriched
Profile completeness: Source-backed profile (78/100)
Indexing directive: index, follow, max-image-preview:large
Recorded profile date: 2025-10-27T17:51:05.665Z

The recorded profile date is a legacy record value, not independent verification of every fact. Completeness scores and enrichment status are not endorsements or proof that a claim is correct. Check each source and any fact-specific review dates.

AI summary

Available profile information

Official website is captured for entity disambiguation.
1 official source linked for verification.
1 supporting source linked.

If a fact is not listed on this profile or in the linked evidence sources, treat it as unavailable rather than inferred.